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Literature Review: Protein folding and molecular chaperones 
 
Newly synthesized proteins must fold to unique three dimensional structures to 
become functionally active. The native fold of protein is encoded in its amino acid 
sequence (1). One of the big challenges of modern science is to uncover the mechanism 
of protein folding (2). How the protein folds to a three dimensional structure is still 
unknown. Anfinsen et al (3) suggested that primary amino acid sequence of proteins has 
all the information to fold into a native conformation. However, the key to proper folding 
of proteins lie in the ability of hydrophobic amino acid side chains to shy away from 
aqueous environment to form an hydrophobic core (4). Proper folding of protein is 
essential for many biological processes such as directing molecules to specific cellular 
locations (1). 
Reasons and consequences of protein misfolding 
 Single domain proteins can bury exposed hydrophobic amino acids residues 
rapidly after the initiation of folding (1, 6). However, multidomain proteins tend to fold 
inefficiently forming partially folded intermediates, which tend to aggregate. The primary 
reason for misfolding of proteins or aggregation of proteins occur due to exposure of 
hydrophobic amino acids residues to the solvent, leading to aggregation of proteins (1,6). 
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The formation of structured fibrillar aggregates are often related with diseases such as 
Alzheimer’s or Huntington’s (6, 7). 
Protein folding requires molecular chaperones 
Living systems have adapted themselves to tackle misfolding abnormalities 
caused in living cell (8, 9). The primary defense against aggregation comes from a set of 
proteins called molecular chaperones. Molecular chaperones helps in proper folding of 
newly synthesized proteins, preventing them from aggregation. Molecular chaperones 
ensure that correct folding is achieved in a highly crowded living cell (10). Molecular 
chaperones also have the ability rescue misfolded and aggregated proteins and make them 
functionally active (8, 9). 
 Most molecular chaperones are called stress proteins as they are induced by 
several other external factors such as heat shock, tissue damage, exposure of cells to 
detergents, heavy metals, infection etc., and (11).  Stress proteins or Heat Shock Proteins 
(Hsp) ranges from molecular size 8 to 150 kDa. The stress proteins are classified into six 
major families Hsp100, Hsp90, Hsp70, Hsp60, Hsp 40 and some other small heat shock 
proteins. 
 Major molecular chaperones families have been studied and more extensive 
reviews of molecular chaperones are reported (12, 13, 14, 15, and 16). My thesis focuses 
on ability of drugs to alter the structure and function Hsp90. I will review the structure 
and function of Hsp90. 
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Heat shock protein 90 (Hsp90) 
 Heat shock protein 90 (Hsp90) is the most abundant protein present in cytosol; 
approximately 2% of the cytosolic protein content is Hsp90 (17). Hsp90 is present at all 
times in cytosol. It is induced further during stress (heat shock, etc.) (18).  
 Hsp90 is highly conserved, human Hsp90 having a 60% sequence homology with 
yeast and 40% homology with E. coli. Hsp90 exists in two highly similar isoforms in 
human cytosol (Hsp90 α and Hsp90 β). Hsp90 isoforms are also present in mitochondria 
(TRAP1) and in endoplasmic recticulum (Grp94). In bacterial cells, Hsp90 homologue is 
called HtpG (high temperature protein G). 
 Many proteins require Hsp90 for their proper function and are therefore called 
“clients” (24). These proteins include steroid hormone receptors and 
serine/threonine/tyrosine kinases (19). However, Hsp90’s ability to fold steroid hormone 
receptors is mainly due to its ability to involve other molecular chaperones in an ordered 
assembly pathway (16). Although, purified Hsp90 shows a weak interaction with variety 
of peptides (20, 21, and 22).  Co-chaperones are the physical and functional partners of 
Hsp90.  
Domain structure of Hsp90 
 Proteolytic studies and sequence alignments have been used to define the 
individual domains on Hsp90. Hsp90 has 3-4 domains, namely the N terminal domain, a 
charged linker region connecting the N terminal and the middle domain region of Hsp90, 
followed by the C terminal domain (Figure 1). 
 The crystal structure of Hsp90’s N-terminal domain was solved for human (23), 
yeast (24), and E. coli (25) homologs. The tertiary structure of the N terminal domain is 
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highly conserved between Hsp90 of E. coli (Htp G) and yeast (Hsp 82). Biochemical and 
crystallographic studies of the N terminal domain of Hsp90 (residues 1-232 in human) 
reveals a binding site for ATP/ADP. The N- terminus ATP binding site was also found to 
bind two Hsp90 inhibitors namely radicicol and geldanamycin (26, 27). Hsp90 function is 
primarily based on its ability to bind and hydrolyze ATP (28). 
 Eukaryotic have Hsp90 a charged linker region connecting the N terminal domain 
and middle domain of Hsp90. This region is very susceptible to proteolysis. This charged 
linker regions are rich in amino acids gluatamic acid, aspartic acid and lysine (29). The 
charged region has been found to increase the ability of Hsp90 to bind to peptide and also 
found to establish a link between ATP and peptide binding to Hsp90 (30). The charged 
linker region is essential for Hsp90 chaperone activity. 
 Recent evidence suggests that the middle domain of Hsp90 was found to 
interact with newly identified protein called AHA1 (activator of Hsp90 ATPase 
homologue 1). This AHA1 promotes the association of N terminal and middle segment of 
Hsp90. This leads to a rapid hydrolysis of ATP (33, 34).  
Figure 1: Domain organization of Human Hsp90α (34)  
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Carboxy-terminal domain of Hsp90 
The carboxy-terminal domain of Hsp90 (residues 609-732) is important for 
dimerization of Hsp90 (34). The C terminal domain is thought to have a nucleotide 
binding site (35) also found to bind an antibiotic called novobiocin (35). The binding of 
ATP to the C terminus of Hsp90 requires the amino terminal nucleotide binding site to be 
occupied by ATP or geldanamycin (36). The C terminus of Hsp90 also contains a highly 
conserved MEEVD motif which is the binding site of Hsp90 co-chaperones containing 
tetratricopeptide repeats (TPR). The mammalian TPR co-chaperones include 
immunophilins (FKBP52, FKBP51), Hop/Sti, PP5, cyclophilin-40) (30, 37, 38).  
 In default conformation, Hsp90 dimerizes through its C-terminal domain. 
N-terminal ATP binding and hydrolysis to promote the transient interaction of two N-
terminal domains leading to the formation of molecular clamp (28). The conformational 
cycle of Hsp90 is discussed in more detail below. 
Crystal structure of the carboxy terminal domain of E. coli (HtpG). 
 The crystal structure of the carboxy terminal domain of E. coli Hsp90 (HtpG) 
reveals a potential drug binding pocket (Figure 2B) (36 “B”) because of the highly 
conserved nature of Hsp90 (E. coli HtpG has 40% sequence homology with human 
Hsp90), this crystal structure acts as a good template to study the drug-binding and 
nucleotide-binding sites on human Hsp90. In HtpG crystal structure, helix 4 and helix 5 
act as a dimerization domain forming Hsp90 homodimer. The helix 4 also contains a 
hydrophobic motif (E. coli amino acid residues 653-669), which has the potential binding 
site of novobiocin.  
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Helix 2 forms another face of the hypthothetical binding site of novobiocin. Even 
though the identity of hydrophobic residues differ from E. coli to human Hsp90 
(601ANMERIMKA608), the hydrophobic nature of helix 2 is preserved. In crystals the 
helix 2 exposed to solvent. In protease nicking assays of the native protein, flexibility of 
this motif makes it vulnerable to trypsinolysis (Figure 2A). In our drug-binding studies, 
we observe that the binding of drugs to the C-terminal domain of Hsp90 induces 
structural and functional changes on Hsp90 (25). 
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Figure 2: HtpG monomer structure (A) Helical structure of the HtpG monomer 
containing helices 4 and 5 that help in dimerization. B) Space fill model of the HtpG 
monomer, revealing a possible binding site for novobiocin. C) Overlapping model of 
HtpG containing both helical structures overlapped with spacefill model. ((Source: PDB, 






Conformational states of Hsp90 
 Hsp90 has weak ATPase activity. Due to this weakness, the ATPase activity of 
Hsp90 remained controversial for some time. Reports from Wiech et al (36) suggested 
that purified Hsp90 failed to function as ATPase. In contrast, reports from Nadeau et al. 
(41) suggested that Hsp90 is an active ATPase. These inconsistencies were resolved 
following the crystallization of N–terminal domain of Hsp90 complexed with ADP (25).  
The ATP bound to Hsp90 is hydrolyzed making Hsp90 an ATPase. Hsp90 shared its 
structural homology with homodimeric ATPases such as gyrase, histidine kinase, Mut L. 
These proteins were called as GHKL superfamily. GHKL family is a strong model that 
guides most of the field’s thoughts about Hsp90. 
 In this model, the N terminal domain binds to ATP through structure called as 
Bergerat fold (42, 43). Binding of ATP causes the dimerization of N terminal domain 
forming a “molecular clamp” (Figure 3, left). The dimerization of N terminal requires the 
pre dimerization of the C-terminal domain of Hsp90 (24). ATP hydrolysis results in the 
disruption of the C-terminal dimerization domain. This is a simple model for studying the 
Hsp90 mechanisms; however the mechanism underlying protein folding by Hsp90 is very 
complex and is still to be explored. 
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Figure 3: The open and closed conformation of Hsp90: 
The open conformation of Hsp90, before the binding of ATP (Figure 3, left), binding of 
ATP induces the N- terminal domain to form lid segments which holds ATP. The ATP 
binding initiates an N- terminal dimerization (Figure 3, right). (Adapted and redrawn 
from Prodromou et al (31). 
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Geldanamycin and molybdate inhibit Hsp90’s ATPase cycle 
The molecular clamp model suggests that Hsp90 exists in two conformational 
states.  The open and closed conformations are characterized by Hsp90’s affinity for 
phenyl sepharose when bound to ADP and its affinity for p23, when ATP is bound (1, 
27). The conformational changes of Hsp90 have been characterized by the effect of 
geldanamaycin and molybdate. Geldanamycin binds to the N-terminal ATP binding site 
of Hsp90 (24, 28). Geldanamycin competes with nucleotides and locks Hsp90 in an open 
conformation (Figure 4A) and is found to mimick the ADP bound conformation of 
Hsp90, preventing the binding of ATP to Hsp90. In contrast to geldanamycin, molybdate 
locks Hsp90 in an ATP or ADP.Pi conformation that interacts tightly with substrates. 
However, molybdate induced conformational changes on Hsp90 require ATP (Figure 
4B). The two different conformations induced by geldanamycin versus molybdate have 
characteristic proteolytic fingerprints (46, 47). Molybdate enforces a protease-resistant 
conformation at a major cleavage site present at Region 600 of human Hsp90 which 
contains an ANMERIMKA motif (47, 48, and 49). However, geldanamycin-bound 




Figure 4: Model of ATPase cycle of Hsp90. (A) Hsp90 in its default conformation 
with its N terminal binding site empty. (B)   Hsp90 containing ATP bound to the N 
terminal domain. (C) Hydrolysis of ATP bound to Hsp90 leading to formation of ADP 
and Pi.     










Novobiocin inhibits Hsp90 function 
 
Hsp90 shares structural homology with the ATP-binding domain of bacterial 
DNA gyrase B protein (24, 27, 43, 51 and 52). Coumarin antibiotics (novobiocin, 
chlorobiocin and coumermycin) were reported to bind to the nucleotide-binding site on 
Gyrase B. Since Hsp90 has a nucleotide-binding site similar to gyrase B protein, Neckers 
et al., analyzed the ability of novobiocin to inhibit chaperone function of Hsp90. They 
found that novobiocin treatment lead to the depletion Hsp90-dependent signal proteins 
(e.g., mutated p53, Raf-1. p60v-src   tumor cells) (53). Similarly, the Hsp90 dependent HRI 
kinase requires Hsp90 and Cdc37. However, novobiocin binding to Hsp90 causes the 
disruption of co-chaperone complex leading to the inhibition of the Hsp90 dependent 
activation/transformation of HRI (37). These results suggest the inhibition of Hsp90 





Figure 5: Structure of (a) ATP and (b) novobiocin 
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Other natural compounds may inhibit Hsp90 
 De novo folding of Lck into active form is mediated by Hsp90 in vivo and can be 
modeled in cell free reticulocyte lysates (RRL). Geldanamycin disrupts the interaction of 
Hsp90 interaction with Lck.  Moreover, the Lck synthesized in the presence of 
geldanamycin was found to be functionally inactive (46).  
 Epigallocatechin gallate (Figure 6), a compound derived from green tea, has been 
recently reported to bind to Hsp90 leading to the inhibition of gene transcription of Aryl 
Hydrocarbon receptor gene (54). This prompted us to determine the effect of 
epigallocatechin gallate on the Hsp90 mediated folding of Lck.  
 
Figure 6: Structure of epigallocatechin gallate  
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The idea that curcumin (Figure 7) might bind and inhibit Hsp90 is very recent. 
Curcumin has been suggested to be an inhibitor of ATPase activity of Hsp90 (Dr.Matts 
personal communication). To investigate the ability curcumin, novobiocin and 
epigallocatechin gallate to inhibit Hsp90 mediated folding of client proteins; we used 
lymphoid cell kinase as a model substrate.  




MATERIALS AND METHODS 
Reagents:
Novobiocin (M.W 634.61, Sigma (5N-6160) was dissolved in DMSO at 0.31 g/10 
ml to make a 50 mM stock. Epigallocatechin gallate (M.W 458.4, Cayman chemical 
(70935) was dissolved in DMSO at 0.1 g/4.4 ml to make a 50 mM stock. Curcumin 
(M.W 368.38, Sigma C7727) was dissolved in DMSO at 0.36g /2 ml to make a 50 mM 
stock. Sodium molybdate (M.W 241.95, Sigma 331058) was dissolved in 2 ml of water to 
make a 100 mM stock. For each of these drugs, aliquots were stored at -20 ˚C and 
discarded after every use. Geldanamycin (M.W 560.6, obtained from Dr. Robert L Matts) 
was of 4µg/µl dissolved in DMSO and stored at -80 ˚C. Geldanamycin stocks were re-
frozen after use.  Rabbit reticulocytes were obtained from Promega. TPCK-treated 
Trypsin (Sigma 035K7676) was dissolved in trypsinolysis Buffer (10mm Tris HCl 
pH7.4, 150mM NaCl, 4mM CaCl2, 0.1mM EDTA) at a concentration of 1µg/µl. Enolase 
(Sigma #112H9645) was prepared as previously described (Cooper et al (1984). 
Hsp90 was detected with two antibodies namely, AC88 (a monoclonal antibody 
recognizing the C terminus of hsp90, was a gift  from Dr. David Toft ,Mayo Medical 
School, Rochester, MN), and antibody PA 3-013 (Affinity Bioreagents, Inc.,) recognizing 
the N terminus of hsp90. Cdc37 was detected using polyclonal mouse anti-cdc37 
antibodies (Hartson et al., (2000). 
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Immunoadsorption wash buffers: 
Buffers  contained 10mM PIPES and varied salt concentrations and detergents: 10 
mM PIPES, 150 mM NaCl, 0.1% Tween pH7.0,(P150T), 10 mM PIPES, 500 mM NaCl, 
0.1% Tween pH 7.0, (P500T), 10 mM PIPES pH 7.0, 50 mM NaCl  pH7.0, (P50). 
contained Kinase wash Buffer contained (0.05M HEPES ,0.5% Triton X100, 0.1M NaCl, 
1mM sodium ortho vanadate, pH7.4) and final Immunoprecipitation  wash buffer 
contained (0.1M PIPES pH 7.0, 1.0M MnCl2 , pH7.4). 
Purification and protease finger printing of recombinant Hsp90:
Hsp90’s C-terminal domain (Q531-D732), a PCR product of human Hsp90 
encoding was ligated to pQE32 as previously described in (Yun et al., 2004). The C- 
terminal domain of Hsp90 was expressed in E .coli and purified to apparent homogeneity 
using HIS-SELECTTM Nickel affinity resin (Sigma P6611) as described (1). The protein 
was eluted from the resin using buffer containing 0.25M imidazole. After elution, 
fractions were analyzed by SDS-PAGE.  Peak fractions were pooled and dialyzed against 
10mM Tris HCl, 75mM Nacl (pH7.4). The dialyzed samples were aliquoted (~80 µg/40 
µl), frozen with liquid nitrogen and stored at -80 ˚C. This protein was designated “Hsp90-
CT” 
 For protease assays, 40µl of purified Hsp90-CT or the Activator of Hsp90 
ATPase (Aha1) protein was thawed, diluted to a final concentration of 0.8 µg/ µl with 60 
µl of 20 mM Tris HCl (pH 7.4) and mixed well. The diluted protein was divided equally 
between two tubes.  Drug was added to one tube and an equal volume of drug vehicle to 
the other. The tubes were mixed well and incubated in ice for 30 minutes. After 30 
minutes, aliquots of drug- treated Hsp90-CT and untreated Hsp90-CT were mixed 25µl of 
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assay buffer (10mm Tris HCl pH7.4, 150mM NaCl, 4mM CaCl2, 0.1mM EDTA) 
containing indicated amounts of trypsin. The trypsinolysis reactions were incubated on 
ice for 6 minutes. The reactions were terminated by adding boiling SDS-PAGE sample 
buffer, and the samples were analyzed by SDS-PAGE. 
Protease finger printing of Hsp90 in situ 
 Rabbit reticulocyte lysate containing an ATP regenerating system (10 mM creatine 
phosphate and 20units/ml creatine phosphokinase) were treated with drug or with drug 
vehicle control, and were incubated for 10 minutes at 30 ˚C. When a second drug was 
present, drugs were added to the reactions after the first incubation and the reactions were 
incubated further for 10 minutes at 30 ˚C. Drug-treated lysate were aliquoted into three 
tubes containing 150 µg/ ml of trypsin in 50 µl of assay buffer (10 mm Tris HCl pH7.4, 
150 mM NaCl, 4 mM CaCl2, 0.1 mM EDTA) and incubated on ice for 8 minutes. The 
reactions were terminated by adding the each reaction to boiling SDS-PAGE sample 
buffer, and the samples were analyzed by SDS-PAGE. The Hsp90 fragments containing 
the C terminus were detected by Western blotting with AC88 antibody. 
Analysis of the effects of drugs on Hsp90 –substrate interactions: 
Wild type lymphoid cell kinase (Lck) was used to determine the effect of 
novobiocin, epigallocatechin gallate, curcumin, geldanamycin on Hsp90s interactions 
with client protein kinase. In vitro transcription/translation reactions contained 9.6 µl of 
TnT Buffer (0.05 M creatine phosphate, 0.01 mM Magnesium acetate, 0.5 M potassium 
acetate, 0.1 mM amino acid-Met, 4 mM NTP’s, pH7.30), 1 µl plasmid DNA (Lck wild 
type), 1 µl of [35S] methionine, 35 µl of rabbit reticulocyte lysate (nuclease-treated) and 1 
µl of SP6 RNA polymerase to a final volume of 50 µl.  Control reactions lacked plasmid 
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and SP6 polymerase. Drugs were immediately added to the individual tubes and mixed 
well. The [35S]Lck was synthesized for 45 minutes at 30 ˚C by coupled 
transcription/translation (TnT). Incorporation of [35S] met was determined by TCA 
protein assay or by autoradiography. Since novobiocin was found to inhibit the TnT 
reaction, novobiocin was added 25 minutes after   initiation of transcription and 
translation.  After 45 minutes of incubation, 45 µl of reaction was used for co-
immunoprecipitation. Control reactions testing the for the direct   inhibition of Lck by 
drugs, drugs were added at the beginning and 80 minutes after initiation of transcription 
and translation. 
Kinase activity of Lck: 
 Protein A resin (Sigma) was used to bind α-Lck antibody by rocking at 4 
˚C for 1.5 hours. The tubes were then washed once with P150T, once with P500, twice 
with P50 wash buffers. After the final wash, the tubes were centrifuged again and the 
supernatant was aspirated using a 20 µl pipette. The immunopellets was then mixed with 
lysate (45 µl) in presence of 250 µl of final immunoprecipitation wash buffers, and 
rocked for 2 hours at 4 ˚C. Immunoadsorbed mixtures were washed once with Kinase 
wash buffer, followed by two washes with final immunoprecipitation wash buffers. After 
the final wash, the tubes were centrifuged again, and the remaining supernatant was 
aspirated off.  
Immediately before use, 10 µl (44 µg) of enolase was mixed with 10µl of enolase 
denaturation buffer (50 mM sodium acetate /acetic acid pH 3.3). The tubes were gently 
mixed and incubated at 30 ˚C for 5 minutes. The tubes were then held on ice until further 
use.  Kinase Assay Mix (KAM) containing 0.5M PIPES pH 7-7.2, 0.1M MnCl2, 22 µg 
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acid denatured enolase, 0.1 mM ATP stock, 32P ATP (40 µCi or 100 µCi) was prepared 
immediately before adding to the immunopellet. KAM was aliquoted (25 µl) equally to 
individual reaction tubes and mixed well for 15 minutes at 30˚C. The reactions were 
terminated by boiling in SDS-PAGE sample buffer and analyzed by SDS-PAGE gel and 






Curcumin, epigallocatechin gallate and novobiocin inhibit Hsp90-dependent folding 
of Lck: 
 To characterize the effect of curcumin, epigallocatechin gallate and novobiocin on 
Hsp90-mediated chaperone function, Lck was used as Hsp90 model substrate. Hsp90 has 
been shown to mediate the proper folding and functioning of Lck (46). For these assays, 
Lck was synthesized and matured in the presence of curcumin, novobiocin, 
epigallocatechin gallate and geldanamycin was immunoadsorbed. The drugs curcumin, 
novobiocin and geldanamycin did not inhibit the efficiency of synthesis of Lck (Figure 
8A, lane 3, 5, 6). However, epigallocatechin gallate inhibited Lck synthesis, thus 
epigallocatechin gallate was added 20 minutes after the on-set of transcription and 
translation. Matured Lck had a different electrophoretic mobility when treated with 
epigallocatechin gallate (Figure 8A, lane 4).  
After immunoadsorption, Lck was assayed with [32P]ATP for its 
phosphotransferase activity.Lysates treated with had a kinase activity of 1% (Figure 7A, 
lane 6) when compared to drug control (DMSO) (Figure 8B, lane 2).  Lysates treated 
with curucmin also produced Lck molecules deficient in kinase activity (67 %) (Figure 
8B, lane 3). Lysates treated with novobiocin produced Lck deficient in kinase activity 
(17%) (Figure 8B, lane 4). Similarly, Lck molecules synthesized in presence of 
epigallocatechin gallate displayed decreased phosphotransferase activity (33%) (Figure 
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8B, lane 4). These results showed that these drugs lead to the production of Lck 
molecules deficient in their phosphotransferase activity.  
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Figure 8: Effect of curcumin, epigallocatechin gallate, novobiocin and geldanamycin 
on Hsp90-mediated folding of Lck. Lck was synthesized in reticulocyte lysate reactions 
containing [35S]-met and curcucmin, novobiocin, and geldanamcyin or drug vehicle. 
Epigallocatechin gallate was added to lysate 20 minutes after the onset of transcription 
and translation and lysates were incubated for further 25 minutes. Lck was isolated by 
immunoadsorption, incubated with [32P] ATP and analyzed by SDS-PAGE and 
autoradiography. Metabolically labeled and kinase assay products are indicated in Panel 
A, Panel B respectively. Under Panel B: numbers represent the densitometry quantitation 




(100%)    (33%)     (67%)      (17%)        (1%) 
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Curcumin, epigallocatechin gallate and novobiocin do not inhibit Lck directly  
 To determine whether curcumin, epigallocatechin gallate and novobiocin 
inhibited Hsp90-mediated folding of Lck versus inhibiting the Lck directly, Lck was 
synthesized and matured in rabbit reticulocyte for 80 minutes in absence of drugs. After 
synthesis and maturation, drugs were added to the lysate, and reactions were chilled on 
ice for 3 minutes on ice. Lck was immunoadsorbed and incubated with [32P]ATP to 
determine its phosphotransferase activity. Autoradiography analysis of the 
immmunoadsorbed Lck suggested that curcumin-, novobiocin- and geldanamcyin- 
treated lysate exhibited a uniform Lck kinase activity, suggesting that these drugs do not 
inhibit kinase directly under these assay conditions (Figure 9B, lower band).  
 Epigallocatechin gallate induced altered electrophoretic mobility on Lck. This 
suggests that epigallocatechin gallate mediates change in the structure of Lck (Figure 9A, 
lane 4). Epigallocatechin gallate treated Lck, showed slightly decreased kinase activity 
(15 %), probably due to the structural modifications induced by epigallocatechin gallate 
(Figure 9B, Lane 4). Epigallocatechin gallate added to Lysate containing immature Lck 
displayed decreased kinase activity (67%). Similarly, epigallocatechin gallate added to 
Lysate containing mature Lck displayed decreased kinase activity (70%), suggesting that 
the decrease in kinase activity of Lck (Figure 9B, lane 4) could not be attributed to 
epigallocatechin gallate 
These results suggest that curcumin, novobiocin and some of epigallocatechin 
gallate do not inhibit Lck directly under these assay conditions.  
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Figure 9: Curcumin, epigallocatechin gallate and novobiocin do not inhibit kinase 
directly. Lck was synthesized in reticulocyte lysate reactions for 80 minutes. After 80 
minutes lysates were treated curcumin, epigallocatechin gallate, novobiocin, 
geldanamycin (or) DMSO. Lysates were then chilled in ice for 3 minutes. Lck was 
isolated by immunoadsorption and Lck kinase activity was analyzed by using [32P]ATP 
and analyzed by SDS-PAGE and autoradiography. Metabolically labeled and kinase 





Effect of curcumin, epigallocatechin gallate and novobiocin on interaction of Lck 
and Hsp90 
 To test the hypothesis that curcumin, epigallocatechin gallate and 
novobiocin disrupted the interaction of Lck with Hsp90, Lck was immunoadsorbed and 
the interaction of Lck with Hsp90 and its co-chaperone Cdc37 was assayed by Western 
blotting. The drug vehicle (DMSO) did not disrupt the interaction of Lck with its Cdc37 
and Hsp90 chaperones (Figure 10B, lane 2). In contrast, geldanamycin completely 
disrupted the Lck interaction with Hsp90, consistent with the previous reports (46).  
Novobiocin (5 mM) disrupted the Lck interaction with Hsp90 (Figure 10B, Lane 5).  
The new candidate epigallocatechin gallate, however did not disrupt the 
interaction of Lck with Hsp90 and Cdc37 completely (80%, 64% respectively) (Figure 
10B, lane 4). Similarly, curcumin did not disrupt the interaction of Lck with Hsp90 and 
Cdc37 completely (80%, 90% respectively) (Figure 10B, lane 3).  These results suggest 
that the novobiocin and geldanamycin disrupts Hsp90 function by inhibiting the Lck 
interaction with Hps90 and Cdc37 (100%). However, epigallocatechin gallate and 
curcumin inhibit Hsp90 function (33%, 67% respectively) without disrupting the 
interaction of Lck with Hsp90 and Cdc37 completely. (Figure 10B, lane 4). However, 
curcumin and epigallocatechin gallate are quantitatively less efficient in disrupting the 




Figure 10: Effect of curcumin, epigallocatechin gallate and novobiocin on 
interaction of Lck and Hsp90 in RRL.  Lck was synthesized and matured in 
reticulocyte lysates translation reactions containing curcumin, novobiocin and 
geldanamcyin or drug vehicle (DMSO). Epigallocatechin gallate was added to lysate 20 
minutes after the onset of transcription and translation and lysates were incubated for 
further 25 minutes. After incubation, Lck was isolated by immunoadsorption and Lck 
interaction with its co-chaperones Hsp90 and Cdc37 was analyzed by SDS-PAGE and 
Western blotting with anti-rabbit Hsp90 and anti-mouse Cdc37. Metabolically labeled 
and Western blot of Lck interaction with Hsp90 and Cdc37 are presented in Panel A, 





Effect of curcumin, epigallocatechin gallate and novobiocin on the interaction of 
mature Lck with Hsp90  
 To test the hypothesis that of maturation Lck would be independent of Hsp90 
machinery, mature Lck was immunoadsorbed after 80 minutes in RRL and assayed by 
Western blot. The drug vehicle (DMSO) did not disrupt the interaction of Lck with its 
Cdc37 and Hsp90 chaperones (Figure 11B, lane 2). Geldanamycin has been reported to 
disrupt the interaction of Hsp90 with its co-chaperones strongly (46). In contrast, I find 
that geldanamycin does not disrupt the interaction between Hsp90, mature Lck and 
Cdc37, suggesting that the data is not interpretable. Together these results suggest that 
the ability of these drugs to inhibit Hsp90 is not related with this association of Hsp90 
with its co-chaperones. 
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Figure 11: Curcumin, epigallocatechin gallate and novobiocin do not inhibit kinase 
directly: Lck was synthesized in reticulocyte lysate reactions for 80 minutes. After 80 
minutes lysates were treated curcumin, epigallocatechin gallate, novobiocin, 
geldanamycin (or) DMSO. Lysates were then chilled in ice for 3 minutes. Lck was 
isolated by immunoadsorption and and Lck interaction with its co-chaperones Hsp90 and 
Cdc37 was analyzed by SDS-PAGE and Western blotting with anti-rabbit Hsp90 and 
anti-mouse Cdc37. Metabolically labeled and Western blot of Lck interaction with Hsp90 





Molybdate and geldanamycin have opposite effects on Hsp90 
 
Drug-induced conformational changes on Hsp90 can be analyzed by proteolytic 
nicking assays. Hartson et al. (46), Yun et al. (38) suggest that in rabbit reticulocyte 
lysate treated with 20 mM molybdate, Hsp90 assumes a protease-resistant conformation. 
However, geldanamycin prevents molybdate-induced conformational changes on Hsp90. 
 To benchmark previous observations and to determine the effects of molybdate 
and geldanamycin on the  conformation of Hsp90, rabbit reticulocyte was treated with 17 
µM geldanamycin or 5 mM molybdate, and their effects on structural conformation of 
Hsp90 was assayed by trypsinolysis. Molybdate induced protease-resistant conformation 
on Hsp90 (Figure 12, lane 3). Geldanamycin was unable to enforce protease-resistant 
conformation on Hsp90 (Figure 12, lane 2), an observation consistent with previous 
observations by (46). 
 Grenert et al. (27) report that geldanamycin and ATP compete for same binding 
site on Hsp90. Molybdate’s inability to  induce a protease-resistant conformation on 
Hsp90 in lysate treated with geldanamycin (Figure 12, lane 4) demonstrates  that the 
molybdate induced protease-resistant conformation of Hsp90 requires ATP to be bound 
to Hsp90,  
Roe et al. (28) indicate that Kd of geldanamycin for Hsp90 is 1.2 µM. However, 
molybdate (20 mM) induced protease-resistant conformation on Hsp90 cannot be 
reversed even in the presence of 17 µM geldanamycin (Figure 12, lane 5), suggesting that 
even very high concentrations of geldanamycin cannot displace bound ATP from Hsp90 
in presence of molybdate. However, In the presence of low concentrations of molybdate 
(5 mM), gelanamycin reverses the molybdate-indcued conformational changes on the C-
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terminal domain of full-length Hsp90. These results suggest that molybdate induced 
proteolytic-resistant on Hsp90 is concentration dependent. 
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Figure 12: Effect of molybdate and geldanamycin on structural conformation of 
Hsp90. Lysates containing ATP-regenerating system were treated with molybdate (5 
mM) and geldanamycin (17 µM) and incubated at 30 ˚C for 10 minutes. Additional drugs 
were added and lysate was incubated for further 10 minutes at 30 ˚C (MoO4 → GA, GA 
→MoO4). Lysates were then trypsinolyzed for 8 minutes at 4 ˚C. Reactions were 
terminated by the addition of boiling SDS-PAGE buffers. Proteins were analyzed by 
SDS-PAGE and Western blotting with antibodies directed against C- terminus of Hsp90. 
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Effect of novobiocin on the conformation of Hsp90 (rabbit reticulocyte lysate) 
 To test the hypothesis that novobiocin inhibited Hsp90 by a molybdate-like 
mechanism, novobiocin and or molybdate were added to rabbit reticulocyte lysate and 
their impact on Hsp90 conformation was compared. As observed previously, 5 mM 
molybdate was able to enforce a conformational change on Hsp90, producing a 
conformational change on the C-terminal domain of Hsp90 (Figure 13, lane 2). 
Novobiocin failed to enforce proteolytic-resistant conformation on Hsp90 (Figure 12, 
lane 4), suggesting that novobiocin has a mechanism of action different from molybdate.  
However, a previous report by Yun et al. (38) suggests that in lysates treated with 
20 mM molybdate and 0-5 mM novobiocin, novobiocin potentiates molybdate’s ability to 
enforce a conformational change on Hsp90. However, in lysates treated with 5 mM 
molybdate and 5 mM novobiocin, novobiocin could not potentiate the molydate effect 
(Figure 13, lane 5). Moreover, novobiocin reverses the molybdate induced 
conformational changes on the C-terminal domain of Hsp90. These results suggest that 
novobiocin fails to potentiate molybdate’s ability to induce proteolytic- resistant 
conformation on Hsp90, suggesting the hypothesis that novobiocin inhibited Hp90 by a 
molybdate-like mechanism is false. 
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Figure 13: Effect of novobiocin on structural conformation of Hsp90. Lysates 
containing ATP-regenerating system were treated with novobiocin (5 mM), molybdate (5 
mM) or geldanamycin (17 µM) and incubated at 30 ˚C for 10 minutes. Additional drugs 
were added and incubated for further 10 minutes at 30 ˚C (MoO4 → NB, NB →MoO4). 
Lysates were then trypsinolyzed for 8 minutes at 4 ˚C. Reactions were terminated by the 
addition of boiling SDS-PAGE buffers. Proteins were analyzed by SDS-PAGE and 
Western blotting with antibodies directed against C- terminus of Hsp90. 
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Novobiocin reverses molybdate induced conformational changes on the C-terminal 
domain of full length Hsp90 
 To benchmark previous observations and to determine the effects of molybdate 
and novobiocin on the conformation of Hsp90, rabbit reticulocyte lysates were treated 
with 20 mM molybdate with an increasing concentration of novobiocin (0-7.5 mM). 
Molybdate induced proteolytic-resistant conformation on Hsp90 (Figure 14, lane 2). 
Increasing concentrations of novobiocin potentiated the molybdate- induced 
conformational changes on C-terminal domain of Hsp90 up to 0-2 mM (Figure 14, lane 
3-5). At a concentrations greater than 5 mM, novobiocin reversed the molybdate- induced 
conformational changes on the C-terminal domain of Hsp90. Novobiocin’s ability to 
completely reverse the molybdate induced conformational change on Hsp90 is evident at 
novobiocin concentration (7.5 mM). These results suggested that novobiocin’s ability to 
potentiate molybdate-induced conformational changes and the ability of novobiocin to 
reverse the effect varied with novobiocin concentration. 
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Figure 14: Novobiocin reverses molybdate induced conformational changes on the 
C-terminal domain of full length Hsp90. Lysates containing ATP-regenerating system 
were treated with molybdate (20 mM) and incubated at 30 ˚C for 10 minutes. Additional 
drugs were added and lysate was incubated for further 10 minutes at 30 ˚C (Moo4 →NB). 
Lysates were then trypsinolyzed for 8 minutes at 4 ˚C. Reactions were terminated by the 
addition of boiling SDS-PAGE buffers. Proteins were analyzed by SDS-PAGE and 
Western blotting with antibodies directed against C-terminus of Hsp90. 
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Effect of epigallocatechin gallate on the conformation of Hsp90 (rabbit reticulocyte 
lysate) 
 Epigallocatechin gallate has been recently reported to inhibit transcription of aryl 
hydrocarbon receptor indirectly by binding to Hsp90 (54). To investigate the effect of 
epigallocatechin gallate on the conformation of Hsp90 and also to test the hypothesis that 
epigallocatechin gallate inhibited Hsp90 by a molybdate-like mechanism, 2 mM 
epigallocatechin gallate was added to the lysate and its impact on Hsp90 conformation 
was assayed by trypsinolysis. As seen previously, molybdate was able to enforce a 
protease- resistant conformation on Hsp90 (Figure 15, lane 2). Epigallocatechin gallate 
was unable to enforce a proteolytic-resistant conformation on Hsp90 (Figure 15, lane 3), 
suggesting epigallocatchin gallate has a mechanism different from molybdate. When 
molybdate was added to epigallocatechin gallate-treated lysate, epigallocatechin gallate 
did not enhance molybdate from inducing a proteolytic-resistant conformation on Hsp90 
(figure 15, lane 5).   
Previous reports by Hartson et al. (47) suggest that geldanamycin was unable to 
reverse 20 mM molybdate’s ability to restructure Hsp90. However, epigallocatechin 
gallate was able to reverse the protease-resistant conformation induced by molybdate 
strongly (Figure 15, lane 4). 
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Figure 15: Effect of epigallocatechin gallate on Hsp90 conformation: Lysates 
containing ATP-regenerating system were treated with epigallocatechin gallate (2 mM), 
molydate (5mM) and incubated at 30 ˚C for 10 minutes. Additional drugs were added and 
incubated for further 10 minutes at 30 ˚C (MoO4 → EG, EG →MoO4). Lysates were 
trypsinolyzed for 8 minutes at 4˚C. Reactions were terminated by the addition of boiling 
SDS-PAGE buffers. Proteins were analyzed by SDS-PAGE and Western blotting with 
antibodies directed against C-terminus of Hsp90. 
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Effect of curcumin on the conformation of Hsp90 (rabbit reticulocyte lysate) 
 Curcumin has been recently suggested to inhibit the ATPase activity of Hsp90 
(personal communication Dr.Robert L Matts). To investigate the effect of curcumin on 
the conformation of Hsp90 and to test the hypothesis that curcumin inhibited Hsp90 by a 
molydate-like mechanism, 1 mM curcumin was applied to lysate and its impact on Hsp90 
conformation was assayed by trypsinolysis. As observed previously, molybdate was able 
to enforce a conformational change on Hsp90 (Figure 16, lane 2). However, curcumin 
was unable to enforce a proteolytic-resistant conformation on Hsp90 (Figure 16, lane 4). 
 To check the hypothesis that curcumin was able to potentiate molybdate-induced 
change in Hsp90 conformation, lysates were treated with curcumin, followed by 
molybdate. Curcumin was unable to strengthen molybdate-induced conformational 
changes on Hsp90 (Figure 16, lane 3), suggesting that curcumin cannot potentiate 
molybdate effect. Additionally, curcumin was unable to prevent molydate from enforcing 
a structural conformation on Hsp90 (Figure 16, lane 3).These results suggest that 
curcumin has a different effect on Hsp90, compared to geldanamycin and novobiocin. 
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Figure 16: Curcumin has unique mechanism of action on Hsp90. Lysates containing 
ATP- regenerating system were treated with curcumin (1 mM) or molybdate (5 mM) and 
incubated for 10 minutes. Additional drugs were added and lysates were incubated for 
further 10 minutes at 30 ˚C (CC →MoO4) . Lysates were trypsinolyzed for 8 minutes at 
4˚C. Reactions were terminated by the addition of boiling SDS-PAGE buffers. Proteins 
were analyzed by SDS-PAGE and Western blotting with antibodies directed against C-
terminus of Hsp90. 
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Curcumin and geldanamycin do not compete for same binding site on Hsp90
 Curcumin has been recently suggested to inhibit the ATPase activity of Hsp90 
(personal communication Dr. Robert l Matts). Curcumin’s inability to prevent molybdate 
from enforcing proteolytic-resistant conformation on Hsp90 (Figure 17, lane 3), suggests 
that curcumin and geldanamycin do not share the same binding site on Hsp90. To test this 
hypothesis, lysates were incubated with 1 mM curcumin, 17 µM geldanamycin and 5 mM 
molybdate and their impact on Hsp90 conformation was assayed by trypsinolysis. As 
observed previously, molybdate was able to induce proteolytic-resistant conformation on 
Hsp90 (Figure 17, lane 2). Curcumin was unable to prevent molybdate from enforcing a 
proteolytic- resistant conformation on Hsp90 (Figure 16, lane 5). Geldanamycin prevents 
molybdate from structuring Hsp90 (Figure 17, lane 3).  Curcumin’s did not prevent 
geldanamycin from having this effect (Figure 17, lane 4). Thus, curcumin and 
geldanamycin did not compete for same binding site on Hsp90 under these assay 
conditions. 
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Figure 17: curcumin and geldanamycin do not compete for same binding site on 
Hsp90. Lysates containing ATP-regeneration system were treated with molybdate (5 
mM), curcumin (1 mM) and geldanamycin (17 µM) and incubated at 30 ˚C for 10 
minutes. Additional drugs were added and incubated for further 10 minutes at 30 ˚C
(DMSO→MoO4, DMSO→GA→MoO4, CC →GA→MoO4, CC→MoO4).  Lysates 
were trypsinolyzed for 8 minutes at 4 ˚C. Reactions were terminated by the addition of 
boiling SDS-PAGE buffers. Proteins were analyzed by SDS-PAGE and Western blotting 
with antibodies recognizing the C-terminus of Hsp90. 
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Curcumin and epigallocatechin gallate do not compete for same binding site on 
Hsp90 
To test the hypothesis that curcumin and epigallocatechin gallate share the same 
binding site on Hsp90, lysates were incubated with 1 mM curucumin, 2 mM 
epigallocatechin gallate and 5 mM molybdate. As observed previously, molybdate was 
able to induce a proteolytic-resistant conformation on Hsp90 (Figure 18, lane 2). 
Curcumin was unable to reverse the molybdate-induced proteolytic-resistant 
conformation of Hsp90 (Figure 18, lane 3). In contrast, epigallocatechin gallate was able 
to reverse the molybdate- induced conformation of Hsp90 (Figure 18, lane 4). Curcumin 
did not inhibit epigallocatechin gallate’s ability to reverse molybdate effect (Figure 18, 
lane 5), suggest that epigallocatechin gallate and curcumin do not compete for binding 
under these assay conditions. 
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Figure 18: Curcumin and epigallocatechin gallate do not compete for same binding 
site on Hsp90. Lysates containing ATP- regenerating system were treated with curcumin 
(1 mM), molybdate (5 mM), epigallocatechin gallate (2 mM) and incubated at 30 ˚C for 
10 minutes. Additional drugs were added and incubated for further 10 minutes at 30 ˚C
(MoO4→ DMSO→CC, MoO4→ DMSO→EG, and MoO4→ CC→EG).  Lysates were 
trypsinolyzed for 8 minutes at 4 ˚C. Proteins were analyzed by SDS-PAGE and Western 
blotting with antibodies recognizing the C-terminus of Hsp90. 
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Curcumin and novobiocin do not compete for same binding site on Hsp90 
 To test the hypothesis that novobiocin and curcumin do not bind to same binding 
site on Hsp90, lysates were incubated with 1 mM curucumin, 5 mM novobiocin and 5 
mM molybdate. As previously described molybdate was able to enforce a proteolytic-
resistant conformation on Hsp90 (Figure 19, lane 2). Curcumin was unable to prevent 
molybdate from enforcing a proteolytic-resistant conformation on Hsp90 (Figure 19, lane 
3). As described previously, novobiocin was able to reverse molybdate- induced 
conformational changes on Hsp90 (Figure 19, lane 4). Curcumin was unable to prevent 
novobiocin’s ability to reverse molybdate- induced conformational changes on Hsp90 
(Figure 19, lane 5). This suggests that curcumin and novobiocin do not compete for the 
same binding site on Hsp90 under these assay conditions.  
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Figure 19: Curcumin and novobiocin do not compete for same binding site on 
Hsp90. Lysates containing ATP- regenerating system were treated with curcumin (1 
mM), molybdate (5 mM), novobiocin (5 mM) and incubated at 30 ˚C for 10 minutes. 
Additional drugs were added and incubated for further 10 minutes at 30 ˚C (MoO4→
DMSO→CC, MoO4→ DMSO→NB and MoO4→ CC→NB).  Lysates were 
trypsinolyzed and incubated for 8 minutes at 4 ˚C. Proteins were analyzed by SDS-PAGE 
and Western blotting with antibodies recognizing the C-terminus of Hsp90. 
 
47
Novobiocin, curcumin, epigallocatechin gallate do not inhibit trypsin 
 Drug-induced conformational changes on Hsp90 were analyzed by 
protease nicking assays.  To test the hypothesis that the drugs novobiocin, curcumin and 
epigallocatechin gallate do not inhibit trypsin directly, the protein Activator of the Hsp90 
ATPase (Aha1) was used as a proteolytic substrate. Aha1 was incubated with drug 
vehicle, novobiocin, curcumin, epigallocatechin gallate and trypsinolysed.  
Aha1 was equally susceptible to trypsinolysis in the absence of drugs (Figure 20, 
lane 5) and in the  presence of novobiocin (Figure 20, lane 2), curcumin (Figure 20, lane 
3), epigallocatechin gallate (Figure 20, lane 4) suggesting that curcumin, epigallocatechin 
gallate and novobiocin to not inhibit trypsin. 
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Figure 20: Novobiocin, curcumin, epigallocatechin gallate, do not inhibit trypsin.
Activators of Hsp90 ATPase (Aha1) was incubated with novobiocin (5 mM), curcumin 
(5 mM), epigallocatechin gallate (5 mM) for 30 minutes on ice. The reactions were 
trypsinolyzed and incubated for 6 minutes at 4 ˚C and analyzed by SDS-PAGE. 
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Novobiocin protects carboxy terminus of Hsp90 from cleavage by trypsin 
 
Yun et al. (38) reported that novobiocin induces the purified truncated Hsp90 C-
terminal domain of Hsp90 (Hsp90-CT, amino acid 584-730) to assume a protease–
resistant conformation invitro.
To confirm and bench mark this observation, Hsp90-CT was treated with 5 mM 
novobiocin or with drug vehicle. Hsp90-CT was susceptible to trypsinolysis in the 
absence of novobiocin (Figure 21, lane 2, 3, 4).  However, Hsp90-CT assumed a 
protease- resistant conformation in the presence of novobiocin (Figure 21, lane 6, 7, 8). 
This experiment confirmed that novobiocin binds to the carboxy terminus of Hsp90 and 
that binding of novobiocin to Hsp90-CT and induced a protease-resistant conformation 
change in Hsp90. 
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Figure 21: Novobiocin alters conformation of C-terminal domain of Hsp90: Purified 
recombinant Hsp90-CT was incubated with novobiocin (5mM) or with drug vehicle 
(DMSO) for 30 minutes on ice. The reactions were then incubated for 6 minutes in 




Epigallocatechin gallate protects Carboxy terminus of Hsp90 from cleavage by 
trypsin 
To test the hypothesis that epigallocatechin gallate similarly alters the 
conformation of Hsp90’s isolated C-terminal domain, Hsp90-CT was treated with 2 mM 
epigallocatechin gallate or drug vehicle (DMSO). Hsp90-CT was resistant to proteolysis 
in the presence of 2 mM epigallocatechin gallate (Figure 22, lane 2, 3, 4).This suggests 
that epigallocatechin gallate binds to the carboxy terminus of Hsp90. The binding of 
epigallocatechin gallate enforced a protease-resistant conformation on Hsp90. 
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Figure 22: Epigallocatechin gallate alters conformation of C-terminal domain of 
Hsp90. Purified recombinant Hsp90-CT was incubated with epigallocatechin gallate 
(2mM) or with drug vehicle (DMSO) for 30 minutes on ice. The reactions were then 
incubated for 6 minutes in presence of indicated concentrations of trypsin and analyzed 
by Coomassie-stained SDS-PAGE. 
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Curcumin protects carboxy terminus of Hsp90 from cleavage by trypsin 
To test the hypothesis that curcumin enforces a protease-resistant conformation on 
the C- terminal domain of Hsp90, Hsp90-CT was treated with 1 mM curcumin or with 
drug vehicle (DMSO).  In the absence of curcumin, Hsp90-CT was susceptible to 
trypsinolysis (Figure 23, lane 2, 3, 4). In contrast, curcumin was able to enforce a 
protease-resistant conformation on Hsp90-CT (Figure 23, lane 6, 7, 8). This suggests that 
curcumin binds to the carboxy terminus of Hsp90.  
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Figure 23: Curcumin alters the conformation of C-terminal domain of Hsp90. 
Purified recombinant Hsp90-CT was incubated with curcumin (1mM) or with drug 
vehicle (DMSO) for 30 minutes on ice. The reactions were then incubated for 6 minutes 






 In my work, I found that novobiocin, epigallocatechin gallate and curcumin 
inhibit Hsp90 function. In rabbit reticulocyte model system (RRL), denovo folding and 
maturation of Lck requires Hsp90 activity (46). Using this assay, my results indicate that 
novobiocin, epigallocatechin gallate and curcumin inhibit Hsp90, leading to production 
of Lck molecules which are deficient in kinase activity. Densitometric analysis of two 
assays suggests that epigallocatechin gallate, curcumin, novobiocin, and geldanamcyin 
inhibit the Hsp90-mediated activation of Lck by 33%, 67%, 83%, 99%, respectively 
(Figure 8). However, more repeats would help us to validate this conclusion statistically.  
Under the assay conditions used in Figure 9, I found that novobiocin, curcumin, 
epigallocatechin gallate do not inhibit Lck directly. When these drugs are added to RRL 
containing mature Lck immediately before immunoadsorption, they do not compromise 
the phosphotransferase activity of Lck subsequently assayed in the presence of millimolar 
concentrations of ATP. This suggests that in the presence of high concentrations of ATP, 
the kinase has a higher affinity for ATP than remaining traces of drugs, demonstrating 
that the drug effects are not mediated due to their direct binding to Lck. Under the assay 
Conditions used in figure 8, 9.  However, when novobiocin, epigallocatechin gallate and 
curcumin are added directly to Lck assays containing micromolar concentrations of ATP, 
these drugs inhibit Lck directly, suggesting that novobiocin, curcumin, epigallocatechin 
gallate may compete with ATP for binding to kinase, leading to an inhibition of kinase 
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activity. This suggests that these drugs can have two different mechanisms when 
assayed under different conditions. The possible ability of novobiocin, curcumin and 
epigallocatechin gallate to compete with the ATP-binding site on Lck suggest that in 
future assays an  alternate substrate for Hsp90, lacking an ATP binding domain, would be 
best suited to clearly determine the ability of these drugs to impair Hsp90’s chaperoning 
ability. 
Curcumin, epigallocatechin gallate and novobiocin have similar effects on the 
interaction of Lck with Hsp90 and its co-chaperones. Geldanamycin- and novobiocin- 
inhibited Hsp90 function by 99%, 83% respectively (Figure 8B, lane 6, 5), while 
disrupting the association of Hsp90 and Cdc37 with Lck by 97.5% and 98% respectively 
(Figure 10B, lane 6, 5). However, curcumin and epigallocatechin gallate inhibit Hsp90 
function by 67% and 33% respectively (Figure 8B, lane 3, 4) without entirely disrupting 
the association of Hsp90 and Cdc37 with Lck (63% and 41%, respectively), (Figure 10B, 
lane 3, 4).  Comparing Hsp90 inhibition versus disruption, I found that these drugs have a 
co-related effect between the efficiency to inhibit and disrupt the complex formation 
between Lck and Hsp90 and Cdc37. These results suggest that these drugs could have 
similar effects on Hsp90’s interaction with Lck, however, the inability of curcumin and 
epigallocatechin gallate to completely disrupt the interaction of Lck interaction with 
Hsp90 and Cdc37 could suggest that curcumin and epigallocatechin gallate are 
quantitatively less efficient in inhibiting Hsp90-mediated activation of Lck and also in 
disrupting the interaction of Hsp90 and Cdc37 with Lck when compared to novobiocin 
and geldanamamycin. 
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Under the assay conditions used in Figure 9, I was surprised to find that matured 
Lck remained associated with Cdc37 and Hsp90. This contradicts previous work showing 
that matured Lck molecules are free of Hsp90 and its co-chaperones. One possibility is 
that drug binding to mature Lck leads to the disruption of the native structure of Lck, 
which in turn invites Hsp90-mediated chaperone activity to refold Lck to its native 
conformation. However, control reactions with 1% DMSO, also showed the prolonged or 
continued interaction of Lck with Hsp90 and Cdc37, arguing that DMSO might alter the 
native structure of Lck. However, the inability of geldanamycin to disrupt the interaction 
of Lck with Hsp90 and Cdc37, suggest that the drug-mediated effects are not chaperone-
related. As another possibility, phosphorylation of Cdc37 in complexes with v-Src kinase 
was reported by Brugge et al. (54). Thus, Lck might mediate the phosphorylation of 
Cdc37. SH2 domain of Lck might then bind the phosphorylated Cdc37. 
A single binding site for novobiocin has been postulated to reside in the C-
terminal domain of Hsp90 (35, 36 B, 38). Crystal structures of C-terminal domain of E.
coli Hsp90 homolog HtpG show a possible binding pocket for novobiocin (Figure 2). The 
helices 3, 4, 5 lines up this binding pocket. Based on the crystal structure, Allan et al (47). 
used point mutations and  identified  a possible binding site of novobiocin which overlaps 
with the hydrophobic region in C-terminal half of  helix 4 and a  part of helix 5 (Residue 
645-673 or human Hsp90 β). The crystal structure also demonstrates that helix 2 has a 
highly flexible loop containing amino acids ANMERIMKA. Allan et al. (47) speculate 
that the binding of coumarin antibiotics promotes the repositioning of helix 2.  
Consistent with these reports, I found evidence that C-terminal domain of Hsp90 
has a site for novobiocin binding. Binding of novobiocin to the C-terminal domain of 
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truncated Hsp90 induces a protease-resistant conformation. This demonstrates that C-
terminal domain of Hsp90 has a binding site for novobiocin (Figure 21). Similarly, 
epigallocatechin gallate also induced a protease-resistant conformation on the C-terminal 
domain of truncated Hsp90 (Figure 22). This suggests that the C-terminal domain of 
truncated Hsp90 has a binding site for epigallocatechin gallate. Curcumin, like 
novobiocin and epigallocatechin gallate, alters the conformation of the C-terminal 
domain of truncated Hsp90, suggesting that the C-terminal domain of Hsp90 has a 
binding site for curcumin (Figure 23). 
Based on crystal structure and reports by Allan et al. (47), I hypothesize that 
binding of these drugs to the hydrophobic cleft encompassing helix 4, helix5 of Hsp90 
causes the flexible helix 2 containing the “ANMERIMKA” to interact with the drugs. 
This causes conformational change on ANMERIMKA motif which then forms a cap like 
structure over the binding site. 
The ability of novobiocin, epigallocatechin gallate and curcumin to interfere with 
the chaperoning function of full length Hsp90 prompted us to investigate whether these 
drugs inhibit Hsp90 function by inhibiting ATP-mediated conformational switching of 
full length Hsp90. The Hsp90 inhibitors geldanamycin and molybdate have opposing 
effects on Hsp90’s ATP-dependent interaction with substrates. Molybdate stabilizes the 
interaction of Hsp90 with clients such as luciferase, Lck, HRI (46) and steroid hormone 
receptors (47in hartson 99). Molybdate locks Hsp90 in its closed conformation, leading to 
the interaction of substrates via salt-resistant interactions (46).  In contrast, 
geldanamycin-treated Hsp90 does not interact strongly with its client proteins. Order-of-
addition experiments show that geldanamycin prevents the molybdate-enforced binding 
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of Hsp90 with clients. However, when applied after molybdate, geldanamycin does not 
reverse the molybdate-induced interaction between Hsp90 and luciferase. These effects 
show that molybdate and geldanamycin have opposing effects on ATP-mediated 
chaperoning function of Hsp90. 
Similarly, geldanamycin and molybdate have opposing effects on Hsp90’s 
conformation. Proteolytic-fingerprinting assays exploit molybdate, an analog of 
phosphate in ATP hydrolysis. This conformational change induced by molybdate 
enforces a protease-resistant conformation on the C-terminal domain of Hsp90 (46). 
However, geldanamyin has no noticeable effect on Hsp90’s fingerprint, suggesting that 
geldanamycin-bound Hsp90 represents Hsp90 in its native state. Order-of- addition 
experiments demonstrate that when geldanamycin is added prior to molybdate, it inhibits 
molybdate from enforcing a proteolytic-resistant Hsp90 conformation. Because 
geldanamycin competes with ATP for binding to Hsp90 (24, 27), Hsp90’s molybdate-
mediated conformational change is ATP-dependent, consistent with the postulated role of 
molybdate as a Pi analog. The inability of molybdate to enforce a proteolytic-resistant 
conformation on the isolated recombinant C-terminal domain of Hsp90, which lacks the 
N-terminal ATP-binding domain of Hsp90, also demonstrates that molybdate binding is 
ATP-mediated. Therefore, molybdate binding is thought to induces conformational 
changes on Hsp90 representing Hsp90 in its ATP, [ADP~P~H20] or ADP.Pi 
conformation. 
Consistent with previous observations, I observed that molybdate binding 
enforces the protease-resistance within the C-terminal domain of full-length Hsp90 
(Figure 12, lane 3). I also found that in order-of-addition experiments, geldanamaycin- 
60
and molybdate bound conformations are not freely exchangeable in the presence of 20 
mM molybdate. In contrast to previous reports, however, I found that in the presence of 5 
mM molybdate, geldanamycin was able to slightly reverse the molybdate-induced 
conformational of Hsp90 (Figure 12, lane 5). This suggests that at low concentrations of 
molybdate, molybdate enforces a protease-resistant conformation which is in equilibrium 
with ADP and nucleotide-free conformations of Hsp90. Addition of geldanamycin shifts 
the reaction cycle towards a dead-end complex, thereby inhibiting molybdate effects on 
Hsp90. 
The ATP-dependent conformational changes on Hsp90 and the effect of 
geldanamycin and molybdate on the ATPase cycle are modeled in Figure 24. In the 
beginning of the reaction cycle, Hsp90 exists in equilibrium between its ATP, ADP and 
nucleotide-free states (Step 1, 2, and 5 of Figure 24). 
In step 3 of the reaction cycle, Hsp90 is represented in its intermediate state of 
ATP hydrolysis [ADP~P~H20]. This induces a proteolytic-resistant conformation on the 
C-terminal domain leading to the structuring of the flexible ANMERIMKA motif.  
In step 4 of the reaction cycle, ATP hydrolysis produces the ADP.Pi bound 
conformation. Release of Pi from ADP causes an empty binding pocket for Pi, as 
represented in step 5 of reaction cycle. The binding and release of Pi is a reversible 
process.  
In the presence of molybdate, molybdate occupies the empty Pi binding pocket on 
Hsp90 (reaction step 6 of Figure 24). Molybdate binding locks Hsp90 in its closed form, 
also locking ADP in its N-terminal pocket and preventing Hsp90 from undergoing its 
ATPase cycle. Binding of molybdate also causes the structuring of ANMERIMKA motif. 
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In the presence of low concentration of molybate, binding and release of molybdate to 
ADP and ADP.MoO4 bound conformation is a reversible process. However, in the 
presence of higher concentration of molybdate, Hsp90 is locked in its molybdate-bound 
conformation as represented in step 6 of reaction cycle. This leads to molybdate-
dependent reversibility of step 5, 6 of Figure 24). In step 7 of  Figure 24, Hsp90 is shown 
in its geldanamycin bound conformation. Binding of geldanamycin (17 µM) causes a 
dead-end complex formation, whereby Hps90 is locked in its open conformation by 
preventing ATP binding. The formation of dead-end complex leads to irreversibility 
between geldanamycin and nucleotide-free Hsp90 conformation. 
 
Figure 24: Effect of molybdate and geldanamayicin on Hsp90 ATPase cycle 
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In my assays, I observed that novobiocin can have a mechanism of action distinct 
from molybdate. Novobiocin could reverse the molybdate-induced structuring of the C-
terminal domain of full-length Hsp90 (Figure 13, lane 4). Similarly, the ability of 
novobiocin to induce a proteolytic-resistant conformation on isolated C-terminal domain 
of Hsp90 suggests that novobiocin has a mechanism of action distinct from molybdate 
(Figure 21), because molybdate-induced conformational changes are dependent on 
binding of ATP to N-terminal domain. Furthermore, 5 mM novobiocin did not structure 
the full length-Hsp90's itself (Figure 13, lane 4). The ability of novobiocin to reverse 
molybdate-induced conformational switching of Hsp90, suggest that novobiocin can have 
a mechanism of action different from molybdate (Figure 13, lane 5). 
 However, Yun et al. suggested that novobiocin structures full-length Hsp90 and 
that molybdate and novobiocin induces conformational changes via cooperative 
mechanism. They observed that in the presence of 20 mM molybdate, 0-5 mM 
novobiocin was able to potentiate molybdate-induced conformational changes. In my 
assays however, molybdate-induced switching of Hsp90 conformation can be inhibited or 
reversed by novobiocin. 
 This inconsistency can be attributed to the difference in molybdate and 
novobiocin concentrations used in the two studies. In my assays, 5 mM molybdate is 
sufficient to induce a proteolytic-resistant conformation on the full length Hsp90, 
compared to 20 mM molybdate used by Yun et al. Consistent with Yun et al, I also found 
that at the 20 mM higher concentration, molybdate-induced conformational changes on 
Hsp90 are potentiated by 5 mM novobiocin. However, I found in my assays that 
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increasing the novobiocin concentration above 5 mM yields an entirely different picture. 
At higher novobiocin concentration novbiocin begins to reverse the molybdate-induced 
conformational changes on Hsp90. (see Figure 25). 
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5 mM 0 mM 7.5 mM 
Protection of full-length Hsp90 
In 20 mM molybdate 
[Novobiocin] 
 
Figure 25: Novobiocin mediates conformational changes on Hsp90. 
Molybdate induced conformational changes on Hsp90 are potentiated in the presence of 
novobiocin. However, novobiocin at a concentration greater than 5 mM reverses 
molybdate-induced conformational change on Hsp90. 
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Novobiocin’s ability to both potentiate molybdate-induced conformational 
changes on full-length Hsp90 and also to reverse the molybdate-induced conformational 
changes on full-length Hsp90 suggests a model of action for these two compounds. (Fig 
(Figure 14). In the 1st step of the reaction cycle, Hsp90 is present in its default 
conformation. In the default conformation, as mentioned earlier, the binding and release 
of ADP is a reversible process.  
In the 2nd step of the reaction cycle, the presence of high concentration of 
molybdate causes Hsp90 to assume an ADP.MoO4 bound conformation. This enforces a 
structural conformation on the ANMERIMKA motif present in the C terminal domain of 
Hsp90 (Figure 13). The 1st and the 2nd step of the reaction cycle are in equilibrium and 
hence are reversible. High concentration of molybdate shifts the reaction cycle to the 
right-hand side strongly enforcing protease-resistant conformation on the C-terminal 
domain of full-length Hsp90.  
In the presence of low concentrations of molybdate, Hsp90 assumes a proteolytic-
resistant conformation (step 1, 2 of Figure 26). Low concentrations of novobiocin 
potentiate re-structuring of the ANMERIMKA motif induced by molybdate (curve 1 of 
Figure 23). However, increasing the concentration of novobiocin brings novobiocin 
concentration high enough to match the affinity for the N- terminal binding site of Hsp90 
(Step 4, 5 of Figure 26). Now novobiocin competes with ATP for binding to the N-
terminal binding site of Hsp90. Binding of novobiocin to the N-terminal domain of 
Hsp90, like geldanamycin prevents ADP and molybdate from enforcing a conformational 
change on the C-terminal domain of Hsp90, as molybdate-induced conformational 
change is ATP dependent. This suggests that novobiocin has two different binding sites 
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on Hsp90. A high affinity binding site at the C-terminal domain of Hsp90 and a low 
affinity site at the N-terminal domain of Hsp90.  
 
Figure 26: Effect of molybdate and novobiocin on Hsp90-ATPase cycle 
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In my assays I observed that epigallocatechin gallate can have a mechanism of 
similar to novobiocin. Like novobiocin, epigallocatechin gallate also could reverse the 
molybdate-induced structuring of the full length Hsp90 (Figure 15, lane 3). Like 
novobiocin, epigallocatechin gallate also induces a proteolytic-resistant conformation on 
isolated C-terminal domain of Hsp90 (Figure 22).  These results suggest that novobiocin 
and epigallocatechin gallate could share the same mechanism of action. 
Epigallocatechin gallate was used only at high concentration (5 mM). However, it 
would be interesting to see if epigallocatechin gallate like novobiocin would potentiate 
the molybdate-induced conformational changes on full-length Hsp90 when used at a low 
concentration. It would also be of great interest to know that whether novobiocin and 
epigallocatechin gallate could compete for the same binding site. These assays would 
reveal if both novobiocin and epigallocatechin gallate share the same mechanism of 
action and probably the same site of action. 
The inability of curcumin to induce a conformational change on the C-terminal 
domain of full-length Hsp90 suggests that it might have a mechanism similar to 
geldanamycin (Figure 23). However, the inability of curcumin to inhibit molybdate-
induced conformational changes on the full-length Hsp90 suggest that  1 mM curcumin 
does not compete with ATP for binding to nucleotide binding site on N-terminal domain 
of full-length Hsp90 (Figure 16, lane 3 ). Similarly, curcumin could not prevent 
geldanamycin’s opposition to molybdate-induced conformational change on C-terminal 
domain of full-length Hsp90, demonstrating that curcumin does not have any effect on 
the conformation of Hsp90. 
68
The inability of curcumin to inhibit or duplicate geldanamycin effects clearly 
suggests that both these drugs do not compete (Figure 17, lane 4). 
Similarly, curcumin does not seem to share the same site and mechanism of action 
with novobiocin and epigallocatechin gallate. Curcumin could not prevent 
epigallocatechin gallate’s ability to reverse molybdate-induced conformational changes 
on C-terminal domain of full-length Hsp90 (Figure 18, lane 5). Curcumin could not 
prevent novobiocin’s ability to restructure the C-terminal domain of full-length Hsp90 
(Figure 19, lane 4). This suggests that curcumin has a unique site of action compared to 
epigallocatechin gallate and novobiocin. 
However, in these assays, curcumin (1 mM) is used at a low concentration under 
these assay conditions, compared to epigallocatechin gallate (5 mM) and molybdate (5 
mM). Curcumin (1 mM) was sufficient to induce a protease-resistant conformation on 
recombinant C-terminal domain of Hsp90. So I used curcumin in the same concentration 
to study its effect on full-length Hsp90. This raises the possibility that inability of 
curcumin to reverse molybdate-induced conformational changes on C-terminal domain of 
full-length Hsp90 could be due to low concentration used in this assay. Moreover, the 
inability of curcumin to prevent epigallocatechin gallate from inducing conformational 
changes on the C-terminal domain of full-length Hsp90 also could also be attributed to 
lack of competitive inhibition between epigallocatechin gallate and curcumin. In future, 
experiments with similar concentration of curcumin and epigallocatechin gallate would 
help us to clearly predict if these drugs share the same binding site. Isothermal 
calorimetry would certainly help us in determining Kd for these drugs. 
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Together this study characterizes new flagship inhibitors of Hsp90 function. 
However, since high concentration of drugs was used in all these assays, it is not 
conclusive whether these drugs would be a specific inhibitors used invivo at 
physiologically relevant concentrations. Interestingly, these drugs have the ability to alter 
the structural conformation of Hsp90, suggesting these drugs would of immense help in 
understanding the ATPase cycle of Hsp90. Future studies on these compounds could 





Novobiocin binds to the carboxy terminus of Hsp90 
Previous experiments with recombinant chicken Hsp90 show Hsp90 bind to 
novobiocin-sepharose. Similarly, binding of C-terminal domain of Hsp90 to ATP-
Sepharose resin is inhibited by novobiocin or soluble ATP, suggesting that both 
novobiocin and ATP bind to same site on C-terminal domain of Hsp90 (35). Yun et al. 
(37) observed that novobiocin induces conformational changes in C terminal domain of 
Hsp90. These observations confirm the ability of Hsp90 to bind novobiocin. However,  
Since novobicoin and Hsp90 are not covalently bonded, it has been a great difficulty to 
study the specific peptide in Hsp90 that bind novobiocin. To overcome this difficulty, I 
will be using photoaffinity novobiocin analogs, which bind to Hsp90 covalently, hence 
the crosslinked peptide could be identified by MALDI-TOF mass spectrometer. 
Novobiocin inhibits co-chaperone binding to Hsp90:
Novobiocin influences Hsp90’s co-chaperone binding ability. Hsp90β pretreated with 
novobiocin was added to denatured rhodanese and the rate of rhodanese aggregation was 
studied by monitoring the increase in the light scattering. Rhodanese aggregation 
increased significantly in the presence of novobiocin.  These results suggest the ability of 
novobiocin to influence the conformation of Hsp90, thereby reducing the co- chaperone 
binding ability of Hsp90. 
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MATERIALS AND METHODS 
Reagents: 
 Sinapinic acid (SA) was purchased from Sigma (530-59-6). MALDI-Matrix 
solutions were prepared fresh as a saturated solution in 30% acetonitrile and 0.1% 
trifluoroacetic acid. 
Photolabile novobiocin analogs (KU-24, KU-25, KU-26, and KU-27) were provided by 
Dr.Brian J Blagg, University of Kansas. These analogs have phenolic ring of novobiocin 
replaced by phenylazide group (Figure 27). The recombinant carboxy-terminal domain of 
Hsp90 was expressed and purified in E. coli as described in Chapter 2. 
UV crosslinking 
Hsp90 CT (~25µg) or apomyoglobin were mixed with 5 mM of each novobiocin 
analogs in a 15 µl reaction containing assay buffer (10 mM Tris HCl pH7.4, 150 mM 
NaCl, 4 mM CaCl2, 0.1 mM EDTA). The reactions were incubated at room temperature 
for 10 minutes. After incubation, reactions were placed on a clean microscopic slide and 
subjected to moderate photo exposure (1-4 flashes with a camera flash bulb) or to UV. 
UV crosslinking was carried out on a Stratagene UV Stratalinker 1800 with 254 nm 
bulbs. The samples were placed 7 cm from the UV bulbs. The power of the instrument 
was set at 184 µJ. The samples were exposed one to four times with the instrument set at 
184 µJ per exposure. After each exposure, aliquots (1.5µl) of the reaction mixed with 
matrix and then spotted on an MALDI plate and allowed to dry. After drying, samples 
were loaded on MALDI-TOF mass spectrometer. The spectra were obtained using on 
Applied Biosystems Voyager-DE Pro MALDI-TOF mass spectrometer operated in the 
linear mode. A total of 500 single spectra (50 X 10 TOF analyses) were accumulated.  
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The parameters used were: grid voltage 91%, guide wire 0.05%. The detector gating was 
set to 1000 kDa. 
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Structure of Photoaffinity analogs of novobiocin: 
 
Figure 27: Structure of photoaffinity analogs of novobiocin. Photoaffinity  
analogs of novobiocin: (Structure and compound courtesy Dr.Brian J Blagg,  




Photoexposure of novobiocin to Hsp90-CT 
 To determine if specific crosslinking could be achieved between Hsp90-CT and 
novobiocin, Hps90-CT was mixed with 5 mM of novobiocin, exposed to one modest 
dose of UV (184µJ) and analyzed by MALDI-TOF mass spectrometry. The theoretical 
mass for Hsp90-CT is 24580, while the observed mass is ~150 m/z higher than 
theoretical mass. This observed error in mass of Hsp90-CT is because the spectra were 
obtained with default instrument calibration without external or internal standards. 
MALDI-TOF analysis showed Hsp90-CT species with an apparent addition of 
~+200 m/z representing a typical matrix adduct. Controls indicated that neither 
novobiocin nor UV alone altered Hsp90-CT mass. (Figure 28, A, B). Similarly, a 
combination of UV and novobiocin did not alter Hsp90-CT mass, suggesting novobiocin 
was unable to crosslink with Hsp90-CT (Figure 28, C).  
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Figure 28: Photo exposure of novobiocin and Hsp90-CT. Hsp90-CT analyzed by 
MALDI-TOF mass spectrometry after (A) UV exposure (B) treatment with novobiocin, 







The inability of novobiocin to crosslink with Hsp90-CT upon UV exposure, 
suggest the non-covalent interaction between Hsp90-CT and novobiocin. The inability of 
novobiocin to covalently bond to Hsp90-CT prompted us to use photoaffinity novobiocin 
analogs, which have phenylazide group replacing phenolic group of novobiocin. The 
phenylazide group upon UV or light exposure forms a nitrene group that can insert to C-
H or N-H site on protein. To first determine if that the photo affinity analogs of 
novobiocin bind to Hsp90, Hsp90-CT was treated with 5 mM novobiocin analog (KU-26)
or with drug vehicle. Hsp90-CT was susceptible to trypsinolysis in the absence of analog 
(Figure 29, lane 1-4), but Hsp90-CT assumed a protease-resistant conformation in the 
presence of analog (Figure 29, lane 5-8). This protection demonstrated that novobiocin 
analog KU-26 binds to the carboxy- terminus of Hsp90.  
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Figure 29: Novobiocin analog KU- 26 alters the conformation of Hsp90-CT. Hsp90-
CT was incubated with novobiocin analog (5 mM KU-26) or with drug vehicle (DMSO), 
for 30 minutes on ice. The reactions were then incubated for 6 minutes in presence of 




Photoexposure (UV) of Hsp90-CT and KU-26 
To determine if specific crosslinking could be achieved between Hsp90-CT and 
analog KU-26, Hsp90-CT was mixed with 5 mM KU-26, exposed to modest dose of UV 
(184µJ) and analyzed by MALDI-TOF mass-spectrometry. MALDI-TOF analysis of the 
control reaction confirmed that UV itself did not induce any crosslinking (Figure 30A).  
UV exposure of Hsp90-CT to KU-24 generated a new Hsp90-CT species mass with an 
apparent addition of ~540 m/z to the parental mass suggesting the covalent crosslinking 
of KU- 24 to Hsp90-CT (Figure 30B).  
Other analogs 
To determine the ability of other analogs to crosslink specifically to Hsp90-CT, 
Hsp90-CT was mixed with 5 mM of KU-25, exposed to one modest dose of UV (184 µJ) 
and analyzed by MALDI-TOF mass-spectrometry (Figure 30C). This resulted in strong 
crosslinking of one to four molecules of KU-25 to Hsp90-CT. Crosslinking of KU-26 
showed less efficient crosslinking of one to four drug molecules of KU-26 to Hsp90-CT 
(Figure 30D).  KU-27 also showed crosslinking efficiency equal to KU-26, weaker than 
KU-25 but stronger than KU-26 (Figure 30E). These results indicate that the position of 




Figure 30: Photoaffinity novobiocin analogs specifically crosslink to the C-terminal 
domain of Hsp90. Hsp90-CT was incubated with drug or drug vehicle (DMSO) exposed 
to UV radiation and analyzed by MALDI-TOF mass spectrometry. Spectrum (A) control 









Crosslinking of novobiocin analogs to Hsp90-CT is highly specific. 
 To determine if crosslinking of novobiocin analog to Hsp90-CT is specific, 
Hsp90-CT was incubated with a mix of both 5 mM novobiocin and 5 mM of novobiocin 
analog (KU-26). Subsequent MALDI-TOF analysis showed most of the crosslinking 
ability of the analog KU-26 was inhibited, in the presence of 5 mM novobiocin. (Figure 
31A vs. 31B). This demonstrates that the crosslinking of analogs is highly specific to the 
novobiocin-binding site on Hsp90-CT. 
To confirm that crosslinking of novobiocin analogs to Hsp90-CT was specific, an 
unrelated protein apomyoglobin was incubated with the most potent crosslinking analog 
KU-25 and subjected to UV exposure. Subsequent MALDI-TOF analysis failed to reveal 
apomyoglobin ion with an addition of ~540 m/z to the parental mass, demonstrating that 
crosslinking is specific to Hsp90-CT (Figure 31C) and was not due to non-specific 





Figure 31: Crosslinking of Novobiocin analogs is highly specific. Purified proteins 
were exposed to UV in the presence of KU-26 and subsequently analyzed by MALDI-
TOF mass spectrometry. (A) Hsp90-CT (B) Hsp90-CT with KU-26 and 5 mM of 




 The photoaffinity novobiocin analog KU-26 binds to the C-terminal domain of 
recombinant Hsp90-CT (Figure  ).   
 MALDI-TOF analysis of the crosslinking between analogs KU-24, KU-25, KU-
26, KU-27 and Hsp90-CT in the presence of modest dose of UV demonstrated new 
species of Hsp90-CT with an apparent addition of ~540 m/z (Figure 30). However, the 
theoretical molecular weight of photoaffinity analogs is 555.49. The observed mass 
difference is 15 Da. The chemistry of phenylazide crosslinking which typically leads to 
loss of two nitrogen atoms. Thus, the mass difference should be 527 Da after 
crosslinking. However, I observed a difference of 540 Daltons. This could be due to the 
addition of water molecules and ring rearrangements after the crosslinking event. 
However, the mass accuracy of my spectrum, the difference in molecular weight 
difference  hence cannot be explored in detail.  
The crosslinking of photoaffinity analogs to Hsp90-CT is highly specific. The 
inability of these analogs to crosslink to an unrelated protein (apomyoglobin) (Figure 
31C), suggest that the crosslinking is highly specific to Hsp90-CT. Competition studies 
shows the crosslinking of KU-26 to Hsp90-CT reduced by ~70% in presence of soluble 
novobiocin, demonstrating that both soluble novobiocin and KU-26 compete for the same 
binding site on Hsp90-CT (Figure 31B).  
 The different photoaffinity analogs exhibit different efficiencies in crosslinking to 
Hsp90-CT (Figure 30A-E).  These results suggest that each analog has different 
efficiency in crosslinking to Hsp90-CT. The presence of carbamyl group acts as a major 
force in driving multiple crosslinking. Even though, KU-24 and KU-25 differ structurally 
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only at the position of carbamyl group and its neighboring hydroxyl group, they show a 
substantial difference in crosslinking efficiency (Figure 24). Similarly, KU-26 and KU-27 
also differ structurally only at position of hydroxyl and its neighboring carbamyl group, 
yet they shown a marked difference in crosslinking efficiency. These results suggest that 
the carbamyl group plays a major role in high affinity binding to Hsp90-CT.  
 Similarly, the presence of azide group in the meta position potentiates 
crosslinking. Crosslinking efficiency of  KU-25 versus KU-27 shows that because KU-27 
differs from KU-25 only in the positioning of nitrene group at ortho position, only two 
molecules of KU-27 crosslinks compared to four by KU-25. Crosslinking efficiency of 
KU-24 versus KU-26 does not show a significantly efficient crosslinking, even though 
KU-24 like KU-25 has an azide group in meta position. This shows that both the nitrene 
and carbamyl group positioning plays a major role in high affinity binding to Hsp90-CT.      
In our studies we have shown that novobiocin binds to Hsp90, and that novobiocin 
analogs could be crosslinked to Hsp90. Future works focusing site of novobiocin 
crosslinking would help us to get a better insight of structure and functional relationships 
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